(Reuters) — Women implanted with Bayer‘s (ETR:BAYN) Essure female sterilization device were more than 10 times more likely to require post-procedure surgery than those who underwent laparoscopic sterilization, according to a study published today in the British Medical Journal. The findings could cast additional doubt on the safety of the Bayer device, which was approved in 2002 as […]
Bayer
Bayer wins PMA for Betaconnect electronic autoinjector
Bayer (ETR:BAYN) said Monday it won FDA premarket approval for its Betaconnect electronic autoinjector for treating relapsing-remitting multiple sclerosis patients on the drug Betaseron. The Betaconnect is the 1st and only electronic autoinjector if its kind to treat RRMS, Whippany, N.J.-based Bayer said. “Bayer has a long legacy of supporting and providing services for the RRMS […]
FDA panel recommends limited use of Bayer’s Essure until more is known about safety
An FDA advisory panel yesterday recommended that the agency limit the use of Bayer‘s (ETR:BAYN) Essure female sterilization device until more is known about its safety, after thousands of women reported serious health issues they attribute to the nickel-titanium implant. Essure, the only approved permanent birth control device in the U.S., is a small metal coil that […]
Essure complaints spike nearly 1,400% in 3 years
The FDA logged a nearly 1,400% spike in complaints filed over the Essure permanent female sterilization treatment made by Bayer (ETR:BAYN), according to a review released yesterday ahead of an FDA advisory panel meeting this week. Essure, the only approved permanent birth control device in the U.S., is a small metal coil that is placed in the […]
Bayer aims at $2.8B IPO for plastics unit Covestro
(Reuters) — Bayer‘s (ETR:BAYN) plastics maker Covestro aims to raise about €2.5 billion ($2.8 billion) with an initial public offering in the 4th quarter, sources said, leaving its parent to focus on drugs and pesticides. Bayer unveiled plans last year to split off the business, formerly known as Bayer MaterialScience, in a move which has improved its share […]
Bayer rebrands material science biz as Covestro
Bayer (ETR:BAYN) said the re-branding of its material sciences business as Covestro is complete, with a separate legal and economic structure for the Pittsburgh-based subsidiary ahead of a planned IPO next year. “Independence will enable us to bring our strengths to bear in global competition more quickly, effectively and flexibly,” Covestro CEO Patrick Thomas said in […]
Bayer opens Costa Rica plant for Essure device
Bayer (ETR:BAYN) yesterday cut the ribbon on a new plant in Costa Rica where it plans to make its Essure permanent contraception device. The 15,000-square foot (1,400m) facility in Barreal de Heredia will initially add about 75 employees to Bayer’s 350-member workforce in Costa Rica, where the company has its Central American and Caribbean headquarters, according to the Costa Rican […]
FDA OKs TVU as 2nd placement test for Bayer’s Essure
(Reuters) — Bayer (ETR:BAYN) said today that the FDA approved using transvaginal ultrasound as an alternate test to confirm if the company’s Essure permanent birth control device has been placed properly. Essure is a small metal coil inserted into woman’s fallopian tubes. Since its FDA approval in 2002, women using the device have sent the safety watchdog more than […]
FDA panel to discuss safety of Bayer’s contraceptive device Essure
(Reuters) — The U.S. Food and Drug Administration said it would discuss the safety and effectiveness of Bayer (ETR:BAYN) AG’s controversial contraceptive device, Essure, in a public panel meeting after receiving more than 5000 complaints, including those of deaths and pregnancies. Essure, which is the only approved permanent birth control device in the United States, is […]
Bayer sells Diabetes Care business to Panasonic Healthcare
(Reuters) — Bayer‘s (ETR:BAYN) has agreed to sell its Diabetes Care business to Panasonic Healthcare Holdings, backed by KKR (NYSE:KKR) and Panasonic (NYSE:PC), for 1.02 billion euros ($1.15 billion), the company said on Wednesday. The deal, expected to be completed in the first quarter of 2016, marks Bayer’s second attempt to divest the blood glucose monitoring […]